Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Inorg Biochem ; 259: 112664, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-39018747

RESUMEN

HIV-1 reverse transcriptase (RT) inhibitors play a crucial role in the treatment of HIV by preventing the activity of the enzyme responsible for the replication of the virus. The HIV-1 Tat protein binds to transactivation response (TAR) RNA and recruits host factors to stimulate HIV-1 transcription. We have created a small library consisting of 4 × 6 polypyridyl Ru(II) complexes that selectively bind to TAR RNA, with targeting groups specific to HIV-1 TAR RNA. The molecule design was conducted by introducing hydroxyl or methoxy groups into an established potent TAR binder. The potential TAR binding ability was analysis from nature charge population and electrostatic potential by quantum chemistry calculations. Key modifications were found to be R1 and R3 groups. The most potent and selective TAR RNA binder was a3 with R1 = OH, R2 = H and R3 = Me. Through molecular recognition of hydrogen bonds and electrostatic attraction, they were able to firmly and selectively bind HIV-1 TAR RNA. Furthermore, they efficiently obstructed the contact between TAR RNA and Tat protein, and inhibited the reverse transcription activity of HIV-1 RT. The polypyridyl Ru(II) complexes were chemical and photo-stable, and sensitive and selective spectroscopic responses to TAR RNA. They exhibited little toxicity towards normal cells. Hence, this study might offer significant drug design approaches for researching AIDS and other illnesses associated with RT, including HCV, EBOV, and SARS-CoV-2. Moreover, it could contribute to fundamental research on the interactions of inorganic transition metal complexes with biomolecules.


Asunto(s)
Complejos de Coordinación , Transcriptasa Inversa del VIH , VIH-1 , ARN Viral , Inhibidores de la Transcriptasa Inversa , Rutenio , Rutenio/química , VIH-1/efectos de los fármacos , VIH-1/enzimología , Humanos , Transcriptasa Inversa del VIH/antagonistas & inhibidores , Transcriptasa Inversa del VIH/metabolismo , Transcriptasa Inversa del VIH/química , Relación Estructura-Actividad , Inhibidores de la Transcriptasa Inversa/farmacología , Inhibidores de la Transcriptasa Inversa/química , Complejos de Coordinación/farmacología , Complejos de Coordinación/química , ARN Viral/metabolismo , Fármacos Anti-VIH/farmacología , Fármacos Anti-VIH/química , Duplicado del Terminal Largo de VIH/efectos de los fármacos
2.
J Inorg Biochem ; 234: 111880, 2022 09.
Artículo en Inglés | MEDLINE | ID: mdl-35679745

RESUMEN

Inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase are central to anti-HIV therapy. Most of their targets are enzymes, while very few could bind to viral RNA. Here we designed four new polypyridyl Ru(II) complexes, which could bind HIV-1 TAR RNA tightly and selectively by molecular recognition of hydrogen bonds, further stabilize the Ru(II)-RNA bound system by electrostatic attraction, and efficiently inhibit the Moloney murine leukemia virus (M-MuLV) and HIV-1 reverse transcriptase. The polypyridyl Ru(II) complexes also have physical and chemical advantages, including high chemical stability and photostability, sensitive spectroscopic responses to HIV TAR RNA, and low toxicity to normal cells. This work also provides valuable drug design strategies for acquired immune deficiency syndrome (AIDS) and other reverse transcriptase related disease research, such as hepatitis C virus (HCV), Ebola virus (EBOV), influenza A virus, and most recently the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).


Asunto(s)
VIH-1 , Inhibidores de la Transcriptasa Inversa , Rutenio , Transcriptasa Inversa del VIH/metabolismo , VIH-1/efectos de los fármacos , Humanos , ARN , Inhibidores de la Transcriptasa Inversa/farmacología , Rutenio/química , Rutenio/farmacología , SARS-CoV-2
3.
Inorg Chem ; 59(20): 14920-14931, 2020 Oct 19.
Artículo en Inglés | MEDLINE | ID: mdl-32951429

RESUMEN

Photodynamic therapy (PDT) using two-photon near-infrared light excitation is a very effective way to avoid the use of short-wavelength ultraviolet or visible light which cannot efficiently penetrate into the biological tissues and is harmful to the healthy cells. Herein, a series of cyclometalated Ir(III) complexes with a structurally simple diimine ligand were designed and the synthetic route and preparation procedure were optimized, so that the complexes could be obtained in apparently higher yield, productivity, and efficiency in comparison to the traditional methods. Their ground state and excited singlet and triplet state properties were studied by spectroscopy and quantum chemistry theoretical calculations to investigate the effect of substituent groups on the photophysical properties of the complexes. The Ir(III) complexes, especially Ir1 and Ir3, showed very low dark toxicities and high phototoxicities under both one-photon and two-photon excitation, indicating their great potential as PDT agents. They were also found to be highly sensitive two-photon mitochondria dyes.


Asunto(s)
Antineoplásicos/farmacología , Complejos de Coordinación/farmacología , Colorantes Fluorescentes/farmacología , Mitocondrias/metabolismo , Fármacos Fotosensibilizantes/farmacología , Células A549 , Antineoplásicos/síntesis química , Antineoplásicos/efectos de la radiación , Complejos de Coordinación/síntesis química , Complejos de Coordinación/efectos de la radiación , Colorantes Fluorescentes/síntesis química , Colorantes Fluorescentes/efectos de la radiación , Humanos , Iridio/química , Iridio/efectos de la radiación , Fotones , Fármacos Fotosensibilizantes/síntesis química , Fármacos Fotosensibilizantes/efectos de la radiación , Oxígeno Singlete/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA